Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: InvestorLady who wrote (763)	5/7/1998 1:07:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1491

I guess coming from the meducal field and not the investor world. today release is what PARS can do. It rereleased info. there is nothing new to those who have followed the co closly, but in view of the hype with entemed. pars states that they too are in the running with their tamoxiphen, They cannot say more as the info is not there. those studies were not done yet. We can only go by the info that we have, This is like AOL will say what their eps will be 5 yrs down line,.The info available so far is great, the price is cheap. people are right to be skeptical. but this is what I like about PARS. Huge upside. with down side protected by sales of Alrex and Lotemax, growth build in, ie growth in US with info by BOL, growth in Europe once introduced, and LeTobra is a sure thing if anything is a sure thing. The valuation for PARS are still based on Alrex. I rather own PARS at # then entremed at 60. Entremed is a great short. Though I personally do not short stocks. If PARS will triple in the next 2 weeks I will sell too, I do expect that it will give more that 5 fold return over longer time.( probably time frame , for hu211 to be in phase 3 with partner and can go to the sky if hu211 is on market and tamoxiphen is on market with broad indication.)